Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-glucuronidase release from leukocytes in children.

M Rister, U Nett

    Klinische Wochenschrift
    |June 18, 1985
    PubMed
    Summary

    Bacterial infections boost beta-glucuronidase release from polymorphonuclear leukocytes (PMNs), enhancing bacterial killing. However, certain cancer drugs inhibit this release, potentially increasing infection susceptibility.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Retrospective analysis of the clinical course of 12 children given the diagnosis essential thrombocythemia].

    Klinische Padiatrie·2004
    Same author

    [Siblings with neonatal progeroid syndrome (Wiedemann-Rautenstrauch)].

    Klinische Padiatrie·2004
    Same author

    [Subacute sclerosing panencephalitis (SSPE)].

    Klinische Padiatrie·2003
    Same author

    Treatment of essential thrombocythemia in childhood.

    Pediatric hematology and oncology·2003
    Same author

    [Intrauterine herpes simplex virus infection].

    Klinische Padiatrie·2001
    Same author

    [Neonatal progeroid syndrome (Wiedemann-Rautenstrauch syndrome): case report and review of the literature].

    Klinische Padiatrie·2000

    Area of Science:

    • Immunology
    • Cell Biology
    • Biochemistry

    Background:

    • Beta-glucuronidase release from polymorphonuclear leukocytes (PMNs) is crucial for bacterial clearance and inflammatory tissue damage.
    • Understanding factors influencing PMN degranulation is vital for managing infections and inflammatory conditions.

    Purpose of the Study:

    • To investigate the impact of various diseases and drugs on the kinetics of beta-glucuronidase release from PMNs.
    • To elucidate the role of PMN degranulation in bacterial infections and its modulation by therapeutic agents.

    Main Methods:

    • Studied the kinetics of beta-glucuronidase release from PMNs stimulated with opsonized zymosan.
    • Compared enzyme release in PMNs from children with bacterial infections, viral infections, and those undergoing specific cancer therapies.

    Main Results:

    • PMNs from children with bacterial infections showed significantly increased beta-glucuronidase release compared to controls.
    • Viral infections led to a delayed release of beta-glucuronidase from PMNs.
    • Cancer chemotherapies (6-mercaptopurine, methotrexate, vincristine) markedly diminished PMN degranulation.

    Conclusions:

    • Bacterial infections stimulate beta-glucuronidase release by PMNs, likely enhancing pathogen clearance.
    • Cytostatic drugs used in cancer therapy inhibit lysosomal enzyme release from PMNs, potentially increasing susceptibility to secondary bacterial infections.
    • Total enzyme activities remained unchanged, indicating modulation of release rather than synthesis.

    Related Experiment Videos